Kytopen Corp and TQ Therapeutics GmbH (TQx) announced a joint agreement granting TQx access to Kytopen’s Flowfect cellular engineering technology through the company’s Technology Access Programme (TAP). This TAP partnership marks another significant milestone in Kytopen’s expanding presence across Europe.

A key driver of TQ Therapeutics’ decision to join the TAP programme was the opportunity to evaluate a next-generation, non-viral cellular engineering technology that can be integrated into its proprietary EXiVO approach—an extracorporeal gene-therapy process that precisely modifies T cells directly from patients’ unprocessed whole blood using the company’s FABfinity cell-selection technology.

As part of the collaboration, the Flowfect technology will be incorporated exclusively as a core module of TQx’s CELLfinity platform, enabling highly efficient delivery of genetic material into defined target cell populations. By combining TQx’s in vivo therapeutic approach with Kytopen’s continuous flow transfection technology—which applies mechanical, electrical, and chemical forces to rapidly engineer hundreds of billions of healthy cells in minutes—the companies aim to advance a new generation of autologous mRNA T-cell therapies designed to revolutionise treatment across multiple disease areas.

“Our partnership with TQ Therapeutics represents a shared vision to transform the landscape of engineered cell therapies. By integrating Flowfect technology with TQx’s groundbreaking in vivo CELLfinity platform, we are not just advancing technology—we are opening the door to entirely new therapeutic possibilities that have the potential to redefine patient care,” said Kevin Gutshall, Chief Commercial Officer, Kytopen.

Through TAP, TQ Therapeutics will receive comprehensive proof-of-concept and process-development support with Flowfect technology. Kytopen will install the Flowfect Tx system on-site and provide dedicated guidance from its Field Applications Team. In addition, TQ Therapeutics will gain access to the Flowfect Discover 96-well optimisation platform, accelerating the progression from early feasibility testing through process optimisation and into clinical and commercial manufacturing scale.

“We are delighted to partner with Kytopen and to integrate the Flowfect technology into our TQx platform. The seamless compatibility of the Flowfect Tx system with our extracorporeal in vivo cell therapy approach enhances our ability to efficiently engineer cells with high precision and safety. Access to the Flowfect Discover platform further accelerates our development pathway—from rapid optimisation through to clinical readiness—strengthening our mission to deliver transformative therapies to patients,” said Christian Stemberger, Chief Scientific Officer, TQ Therapeutics.